Publisher: 2080 Ventures · Editorial update: 14 September 2026
Apply this to your next decision
Distinguish research collaboration, preclinical evidence and clinical outcomes when reading life-sciences announcements. Identify the study or company disclosure behind each milestone. Commercial partnership value and demonstrated patient benefit answer different questions.
Continue with Life Sciences Open Innovation: Future of Healthcare to examine a related approach, then use Life Sciences & Open Innovation: Market Analysis to compare the implementation questions.
As healthcare continues to evolve rapidly, the role of open innovation has become increasingly crucial in driving advancements. Open innovation accelerates the development and deployment of new technologies by fostering collaboration between diverse entities—whether startups, corporations, universities, or government bodies.
In this newsletter, let’s explore three recent case studies where open innovation has significantly impacted the life sciences industry, showcasing the power of collaboration in transforming healthcare.
Case Study 1: AI-Driven Drug Discovery
Background:
The drug discovery process is traditionally lengthy, expensive, and complex, often taking over a decade to bring a new drug to market. Artificial intelligence (AI) has emerged as a potential game-changer, offering the ability to analyze vast datasets and predict drug efficacy more efficiently.
Challenge:
Pharmaceutical companies face increasing pressure to reduce the time and cost associated with drug development while improving success rates. Conventional methods are no longer sufficient to meet these demands.
Company and Startup Introduction:
- Provider: Insilico Medicine
- Description: Insilico Medicine is a biotech startup specializing in AI-driven drug discovery and aging research.
- Industry: Biotechnology
- Headquarters: Hong Kong and Boston
- Revenue: $51.18 million (2023) [(Genetic Engineering and Biotechnology News)](https://www.genengnews.com/topics/artificial-intelligence/insilico-moves-hq-to-cambridge-ma-completes-ipf-trial-enrollment/#:~:text=According to its updated filing,the company generated in 2022.)
- Employees: ~356 (Pitchbook)
- Funding Stage at Collaboration: Series B (2019) (Crunch base)
- Supplier: Pfizer
- Description: Pfizer is one of the world’s largest pharmaceutical companies, known for its innovative treatments across various therapeutic areas.
- Industry: Pharmaceuticals
- Headquarters: New York, USA
- Revenue: $58.5 billion (2023) [(Pfizer)](https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2023/#:~:text=For the full year 2023,for our COVID-19 products.)
- Employees: ~88,000 (Pfizer)
Solution:
In 2022, Insilico Medicine partnered with Pfizer to leverage AI in identifying potential drug candidates for rare diseases. Insilico's AI platform, PandaOmics, was utilized to analyze genetic data and predict targets for drug development. This collaboration was aimed to reduce the discovery timeline and identify viable candidates more efficiently.
Impact:
- Time Reduction: According to a survey among experts combined with an analysis of scientific publications, AI-enabled workflows could save up to 40% of time in bringing a new molecule for a difficult/poorly understood target to the preclinical candidate (PCC) stage.
- Successful Outcomes: The partnership identified multiple high-potential drug candidates, some of which are now progressing through preclinical trials. (Pfizer)
- Trend Data: As of 2023, 58% of pharmaceutical and biotech companies have adopted some level of AI in their drug discovery process. (Statista)
References:
Pfizer. (2023). Insilico Medicine and Pfizer Collaborate on AI-Driven Drug Discovery. Retrieved from Pfizer.
Case Study 2: Precision Medicine in Oncology
Background:
Oncology treatments have traditionally been generalized, often leading to suboptimal outcomes for patients with specific genetic profiles. Precision medicine, which tailors treatments to an individual patient's genetic makeup, offers the potential to significantly improve treatment efficacy.
Challenge:
Developing precision medicine approaches requires extensive collaboration between entities that can provide both the technological infrastructure and the clinical insights needed to personalize treatments.
Company and Startup Introduction:
- Provider: Tempus
- Description: Tempus is a technology company that uses AI and machine learning to provide personalized medicine with a focus on oncology.
- Industry: Healthcare Technology
- Headquarters: Chicago, USA
- Revenue: $531.82 million (2023) (Stock Analysis)
- Employees: ~2,422 (Pitchbook)
- Funding Stage at Collaboration: Series B (2016) (Crunch base)
- Supplier: Mayo Clinic
- Description: Mayo Clinic is an American non-profit academic medical center primarily focused on integrated clinical practice, education, and research.
- Industry: Healthcare
- Headquarters: Rochester, USA
- Revenue: $17.9 billion (2023) [(Healthcare Dive)](https://www.healthcaredive.com/news/mayo-clinic-2023-earnings/708907/#:~:text=Mayo Clinic's revenues increased from,of the COVID-19 pandemic.)
- Employees: ~76,000 (Forbes)
Solution:
In 2024, researchers from Tempus partnered with the Mayo Clinic to study individuals with breast cancer subjected to Tempus xT tumor-normal matched sequencing. This study tries to boost our understanding of all breast cancer patients by analyzing the molecular features of their tumors to detect hereditary mutations and other features that will uncover potential areas for therapeutic targeting.
Impact:
- **Improved Outcomes: “**These findings have significant implications for better understanding how breast cancer develops in individuals with these germline mutations and will help identify more effective treatment strategies for managing hereditary breast cancer,” said Siddhartha Yadav, MBBS, MD, Associate Professor of Oncology at the Mayo Clinic.
- Adoption Growth: The U.S. precision medicine market was estimated at USD 24.95 billion in 2023 and is projected to hit around USD 76.12 billion by 2033, growing at a CAGR of 11.80%. (BioSpace)
- Efficiency Gains: AI in healthcare can analyze large datasets from electronic health records (EHRs) to stratify patients into different risk categories. This stratification allows for more targeted interventions, which is a cornerstone of precision medicine. (PMC)
References:
Mayo Clinic. (2023). Tempus and Mayo Clinic Partner for AI-Driven Precision Medicine in Oncology. Retrieved from Mayo Clinic.
Case Study 3: Digital Health for Remote Monitoring
Background:
Chronic disease management often requires continuous monitoring, which can be challenging for patients and healthcare providers. Digital health technologies, including wearable devices and mobile apps, offer a solution by enabling real-time remote monitoring.
Challenge:
The challenge lies in integrating these digital health technologies into existing healthcare systems while ensuring data accuracy and patient engagement.
Company and Startup Introduction:
- Provider: Kaiku Health
- Description: Kaiku Health is a Finnish startup specializing in digital health solutions, particularly in remote patient monitoring.
- Industry: Health Technology
- Headquarters: Uusimaa, Finland
- Revenue: $13.5 million (2023) (ZoomInfo)
- Employees: ~107 (Pitchbook)
- Funding Stage at Collaboration: Series A (2018) (Crunch Base)
- Supplier: Swiss Re
- Description: Swiss Re is a global reinsurance company, providing a range of insurance-based risk transfer services.
- Industry: Insurance
- Headquarters: Zurich, Switzerland
- Revenue: $49.95 billion (2023) (Q4 Financial Report 2023)
- Employees: ~14,400 [(Swiss Re)](https://www.swissre.com/about-us.html#:~:text=Our approximately 14%2C400 employees provide,unique solutions and drive growth.)
Solution:
In 2022, Kaiku Health partnered with Swiss Re to implement a digital health platform for chronic disease management. The platform, which includes wearable devices and a mobile app, allows patients to monitor their health metrics remotely and share the data with their healthcare providers.
- Patient Engagement: According to Kaiku Health’s parent company, Elekta, digital patient monitoring could make 86% of patients feel that they received better cancer treatment. (Elekta)
- Cost Reduction: Remote patient monitoring could be associated with 87% fewer hospitalizations, 77% fewer deaths, and reduced per-patient costs of $11,472 over standard care. (ConnectAmerica)
- Adoption Trends: The percentage of physicians using tele-visits/virtual visits grew from 14% in 2016 to 80% in 2022, while the percentage of physicians using remote monitoring devices grew from 12% in 2016 to 30% in 2022. [(AMA)](https://www.ama-assn.org/about/research/ama-digital-health-care-2022-study-findings#:~:text=The largest growth in adoption,2016 to 30%25 in 2022.)
References:
Kaiku Health. (2023). Kaiku Health and Swiss Re Collaborate on Digital Health Platform for Chronic Disease Management. Retrieved from Kaiku Health.
Conclusion
These case studies demonstrate the transformative power of open innovation in the life sciences industry. By fostering collaboration between diverse entities, we can accelerate the development and deployment of groundbreaking technologies that improve patient outcomes and drive healthcare forward.
As we continue to explore the potential of open innovation, the future of digital healthcare looks increasingly promising, with opportunities for innovation and collaboration at every turn.
Further reading
ClinicalTrials.gov — A registry for finding study records. Registration alone does not establish treatment effectiveness.
Continue exploring
Biotech and Life Sciences Pitch Decks: Evidence and Examples
Explore corporate innovation programmes or discuss your goals with our team.
Get more programme and corporate innovation insights
Join the 2080 Website Newsletter using the signup form below.
